Современные аспекты применения Зофрана


Л.Г. Жукова

Тошнота и рвота является частым осложнением цитостатической терапии, подразделяясь на острую, отсроченную и предшествующую (развивается до лечения). Рассматриваются современные подходы к профилактике и лечению различных типов тошноты и рвоты, встречающихся в онкологической практике. Наиболее эффективными противорвотными средствами, используемыми с этой целью, являются антагонисты 5-НТ3 рецепторов, в первую очередь Зофран (ондансетрон) - наиболее изученный и широко применяемый препарат данной группы. Обсуждаются схемы применения Зофрана (в т. ч. в комбинации с дексаметазоном) при различных режимах химиотерапии. Препаратами выбора антагонисты 5-НТ3 рецепторов являются и при тошноте и рвоте, обусловленных лучевой терапии. Приводятся последние рекомендации по применению Зофрана для профилактики острой тошноты и рвоты при проведении химиотерапии. Подчеркивается, что многообразие лекарственных форм Зофрана (в т. ч. новых - лингвальные таблетки, сироп, суппозитории) позволяет использовать его практически в любых клинических ситуациях.

Литература






  1. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982;66:1487.
  2. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10;1969–75.
  3. Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992;66:192–97.
  4. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994;51(1):113–38.
  5. Needles B, Miranda E, Garcia Rodriguez FM, et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. Support Care Cancer 1999;7:347–53.
  6. Roila F, De Angelis V, Cognetti F, et al. Ondansetron vs. granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis. Proc Am Soc Clin Oncol 1995;14:523.
  7. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987;69:1353.
  8. Dilly SG, Friedman C, Yocom K. Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis. Proc Am Soc Clin Oncol 1994;13:436.
  9. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966–73.
  10. Peterson C, Hursti TJ, Borjeson S, et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer 1996;4:440–46.
  11. Joss RA, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients: Swiss Group for Clinical Cancer Res (SAKK). Ann Oncol 1994;5:253–58.
  12. Ahn MJ, Lee JS, Lee KH, et al. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. Am J Clin Oncol 1994;17:150–56.
  13. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994;12:596–600.
  14. Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?. BMJ 1991;303:1423–26.
  15. Grala R, Lichinitser M, Van der Vegt, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology 2003;14:1570–77.
  16. Research TIGfA. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin induced delayed emesis. Clin Oncol 1997;15:124–30.
  17. Rittenberg CN, Gralla REJ, Lettow LA, et al. New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109 patient trial. Proc Am Soc Oncol 1995;14:526.
  18. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675.
  19. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: a double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108.
  20. Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis: Ondansetron Delayed Emesis Study Group. Ann Oncol 1996;7:945–52.
  21. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338.
  22. Navari RM, Reinhardt RR, Gralla RJ. Reduction of cisplatin induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340:190.
  23. Burish TG, Carey MP. Conditioned aversive responses in cancer chemotherapy patients: Theoretical and developmental analysis (review), 1986.
  24. Burish TG, Shartner D, Lyles JN. Effectiveness of multiple site EMG biofeedback and relaxation in reducing the aversiveness of cancer chemotherapy. Biofeedback Self-Reg 1981;6:523.
  25. Morrow GR, Morrell BS. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476.
  26. Feyer PC, Stewart AL, Tilbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Supportive care in cancer 1998;6:253–60.
  27. Priestman TJ, Roberts JT, Lucraft CH, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high dose upper abdominal irradiation. Clin Oncol 1990;2:71.
  28. Sledge GW, Einhorn LH, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple day cisplatin based therapy. Cancer 1992;70:2524–28.
  29. deBoer M, deWit R, Stoter J, et al. Possible lack of full cross-resistance of 5HT3 antagonists: a pilot study. Cancer Res Clin Oncol 1995;121: 126–27.
  30. Falkson C, Falkson H. Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy. Oncology 1995;52:427–31.
  31. Domingues-Ortega L, Cubedo-Cervera R, Cortes-Funes, et al. Sleep protect against chemotherapy induced emesis. Cancer 1996;77:1566–70.
  32. Mantovani G, Maccio A, Alessandro B, et al. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941–48.
  33. LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 1999;11:340–47.
  34. Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 1999;21:492–502.
  35. Davidson NG, Paska W, Van Belle S, et al. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group. Oncology 1997;54:380–86.
  36. Fumoleau P, Giovannini M, Rolland F, et al. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group. Oral Oncol 1997;33: 354–58.
  37. Einarson А. (The Hospital for Sick Children in Toronto), Inter J Obstetr Gynecol 2004.



Бионика Медиа